48 results about "Sensorineural hearing loss" patented technology

An implantable middle ear hearing device having a tubular vibration transducer to drive a round window is designed to input sound to a round window opposite an oval window in an inner ear. The tubular vibration transducer has a unique structure that does not attenuate the magnitude of a signal, particularly, in a high frequency band. Sound delivery effect is much higher than those of conventional schemes. It is also possible to minimize difficulties associated with and problems resulting from the operation, which the conventional methods would have. Further, the transducer can have a relatively less compact than ossicle contact type transducers, and thus be easily fabricated. The hearing device can be applied to a sensorineural hearing loss patient with the ossicle damaged. Moreover, since sound is directly transmitted without through the ear drum and the ossicle, high efficiency sound delivery is achievable and hearing loss compensation are easy.

The present invention relates to a round window driving transducer for easy implantation and an implantable hearing device having the same. The round window driving transducer is implantable in the round window of the cochlea in the middle ear cavity, and has excellent high frequency characteristics, which can assist patients with sensorineural hearing loss to hear sound better. The round window driving transducer can be placed inside the middle ear cavity, radiate sound with high efficiency, and be implanted by surgery using a fixing part formed with shape memory alloy, shape memory resin, or a bendable spring structure. Further, the round window driving transducer can overcome problems of the prior art, such as a difficult surgery and low vibration efficiency, which would inevitably occur when floating mass transducers are implanted in a drilled groove in the bone or when various types of piezoelectric transducers are implanted in the round window.

The invention relates to an actuator for hearing compensation and a hearing aid device with the same. The actuator comprises a fixed bracket, a piezoelectric member and a coupling rod, wherein the fixed bracket is fixedly implanted on skull through operation; the piezoelectric member is composed of piezoelectric stacks; one end of the piezoelectric member is connected with the fixed bracket and fixed thereby while the other end thereof is connected with the base part of the coupling rod; and the acting end of the coupling rod acts on one otosteon of middle ear. The hearing aid device can be used in high magnetic fields, which has no requirement on complete hearing chain of patients, so the device can cure patients with mixed hearing loss and damaged ossicular chain. In addition, the hearing aid device is featured with high frequency and high gain, which can compensate bad sensorineural hearing loss.

The present invention relates generally to novel hydantoin derivative compounds, pharmaceutical compositions containing such compounds, and methods for their use in preventing and/or treating neurological disorders, including physically damaged nerves and neurodegenerative diseases; for treating alopecia and promoting hair growth; for treating vision disorders and/or improving vision; for treating memory impairment and/or enhancing memory performance; and for treating sensorineural hearing loss by administering such compounds.

The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition includes compounds which function as free radical traps such as phenyl butyl nitrone (PBN), free radical scavengers, such as edaravone, resveratrol, ebselen and iron chelator and compounds from the family of antioxidant compounds including, but not limited to, N-acetylcysteine (NAC), Acetyl-L-Carnitine (ALCAR), glutathione monoethylester, ebselen, D-methionine and carbamathione. The compositions of the current invention may be delivered by injections or orally.

The invention discloses a drug or health care product for preventing and treating hearing loss and relates to the technical field of biological medicine and health care products. Aiming at the defects that there are not many drugs for treating hearing loss in the market currently, the treatment effect is poor, and health care products with the corresponding function are unavailable, the effective and well-targeted drug for preventing and treating hearing loss and the corresponding health care product, especially the drug which has a special effect on sensorineural hearing loss including age-related hearing loss, noise induced hearing loss and sudden hearing loss and the corresponding health care product are provided. The drug or health care product contains the active constituent nicotinamide mononucleotide. The drug or health care product has the advantages of being capable of becoming effective quickly, high in treatment effect, stable in efficacy, free of toxic or side effect on human body and the like.

The invention discloses an artificial auditory ossicle for treating a mixed hearing damage. The artificial auditory ossicle comprises a top tray, a connection bar, a piezoelectric device and a stapes clamp, wherein the top tray is fixed on an eardrum in an operation implantation manner; one end of the connection bar is connected with the top tray; the other end of the connection bar is connected with the base end of the piezoelectric device; the piezoelectric device mainly comprises piezoelectric stacks; the action end of the piezoelectric device is connected with the base end of the stapes clamp; and the action end of the stapes clamp directly acts on stapes. The artificial auditory ossicle not only can be used for replacing a damaged auditory ossicle like a traditional artificial auditory ossicle so as to treat a conductive hearing loss, but also has an active shock excitation ability so as to compensate an accompanied sensorineural hearing loss. In addition, the active auditory ossicle can work under the environment of high-intensity magnetic field and has the advantages of low energy consumption and good high-frequency gain. The artificial auditory ossicle also has the advantages of simple structure, high ireliability, low manufacturing cost and low price, thereby being convenient for widely popularization.

The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.

A TMC1 gene mutant and applications thereof are disclosed. The invention relates to a separated nucleic acid encoding the TMC1, a separated polypeptide, a method of screening a biological sample susceptible to the sensorineural hearing loss, a system of screening the biological sample susceptible to the sensorineural hearing loss, and a kit for screening the biological sample susceptible to the sensorineural hearing loss. Compared with SEQ ID NO:1, the separated nucleic acid encoding the TMC1 is provided with at least one mutant selected from c.589G>A and c.1171C>T. By detecting whether the biological sample comprises the mutants or the mutant, whether the biological sample is susceptible to the sensorineural hearing loss can be effectively detected.

The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.

The present invention relates to a composition for preventing or treating hearing loss, containing an HMG-CoA reductase inhibitor and, more specifically, to a composition for preventing or treating diabetes-mediated hearing loss, containing, as an active ingredient(s), one or more types selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. A pharmaceutical composition containing an HMG-CoA reductase inhibitor, according to the present invention, inhibits auditory cell death caused by diabetes, and thus is very useful as an agent for preventing or treating diabetes-mediated sensorineural hearing loss.

The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.

Provided are a pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma, and a method of preventing or treating sensorineural hearing loss or tinnitus using the same.

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of a stereocilin protein, and the use of these compositions to treat non-syndromic sensorineural hearing loss in a subject.

A pharmaceutical composition containing forskolin and retinoic acid as active ingredients which is suitable for preventing or treating sensorineural hearing loss is disclosed. A pharmaceutical composition containing forskolin and retinoic acid as active ingredients has an excellent effect of preventing, alleviating or treating hearing loss caused by ototoxic drugs during anticancer treatment, and thus is useful as a pharmaceutical composite preparation capable of reducing side effects of anticancer drugs and, additionally, as an agent for preventing or treating sensorineural hearing loss.

The invention discloses a kit for DIAPH1 mutation detection, a pathogenic gene of delayed sensorineural hearing loss. The kit includes reagents for extracting DNA from samples to be tested, PCR reaction reagents for amplifying DNA samples and reagents for sequencing PCR amplification products; and the PCR reaction reagents for amplifying DNA samples include PCR primers. The kit of the invention isused to detect whether patients have NM_001314007:c.3575-2A>G mutation in DIAPH1 gene, so as to diagnose the cause of delayed sensorineural hearing loss. Therefore, the kit is helpful for the development of clinical screening of DIAPH1 mutation in patients with delayed sensorineural hearing loss, providing a basis for the diagnosis of delayed sensorineural hearing loss.